Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the Raf kinases in human cancer: the Raf dimer dilemma.

British journal of cancer - 1 Jan 2018

Durrant David E, Morrison Deborah K

Abstract excerpt

The Raf protein kinases are key intermediates in cellular signal transduction, functioning as direct effectors of the Ras GTPases and as the initiating kinases in the ERK cascade. In human cancer, Raf activity is frequently dysregulated due to mutations in the Raf family member B-Raf or to altera...

Topics

Drug Resistance, Neoplasm
Humans
Imidazoles
Models, Molecular
Molecular Targeted Therapy
Mutation
Neoplasms
Oximes
Protein Kinase Inhibitors
Protein Multimerization
Signal Transduction
Vemurafenib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

raf Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 29235562
DOI: 10.1038/bjc.2017.399
PMCID: PMC5765234

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-29235562-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the Raf kinases in human cancer: the Raf dimer dilemma.PMID 29235562Read ↗

Novel RAF-directed approaches to overcome current clinical limits and block the RAS/RAF node.Semantic proximity Read ↗

Path Forward for RAF Therapies: Inhibition of Monomers and Dimers.Semantic proximity Read ↗

The importance of Raf dimerization in cell signaling.Semantic proximity Read ↗

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors.Semantic proximity Read ↗

The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants.Semantic proximity Read ↗

Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.Semantic proximity Read ↗

Aberrant B-Raf signaling in human cancer -- 10 years from bench to bedside.Semantic proximity Read ↗

The Discovery of Exarafenib (KIN-2787): Overcoming the Challenges of Pan-RAF Kinase Inhibition.Semantic proximity Read ↗

Mechanism and consequences of RAF kinase activation by small-molecule inhibitorsSemantic proximity Read ↗

RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition.Semantic proximity Read ↗

B-Raf Inhibition in the Clinic: Present and FutureSemantic proximity Read ↗

Interactome dynamics of RAF1-BRAF kinase monomers and dimers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.